BSE Live
Jan 29, 16:01Prev. Close
1140.15
Open Price
1135.80
Bid Price (Qty.)
1140.00 (1)
Offer Price (Qty.)
1150.55 (6)
NSE Live
Jan 29, 15:59Prev. Close
1139.90
Open Price
1140.40
Bid Price (Qty.)
1150.60 (541)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Aurobindo Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 3,319.60 | 2,885.25 | 2,351.12 | 1,979.76 | 1,472.36 | |
| Less: Excise/Sevice Tax/Other Levies | 67.54 | 90.35 | 116.49 | 103.67 | 78.72 | |
| Revenue From Operations [Net] | 3,252.06 | 2,794.90 | 2,234.63 | 1,876.09 | 1,393.64 | |
| Total Operating Revenues | 3,252.06 | 2,794.90 | 2,234.63 | 1,876.09 | 1,393.64 | |
| Other Income | 110.03 | -197.18 | 155.32 | 95.15 | 22.02 | |
| Total Revenue | 3,362.09 | 2,597.72 | 2,389.95 | 1,971.24 | 1,415.66 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 2,126.14 | 1,859.60 | 1,575.89 | 1,349.09 | 1,034.93 | |
| Purchase Of Stock-In Trade | 19.36 | 9.47 | 11.79 | 48.07 | 15.28 | |
| Operating And Direct Expenses | 59.14 | 46.08 | 43.04 | 39.22 | 23.21 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -147.48 | -28.94 | -31.18 | -72.47 | -24.81 | |
| Employee Benefit Expenses | 232.62 | 177.18 | 148.70 | 112.88 | 79.21 | |
| Finance Costs | 54.30 | 72.17 | 52.73 | 70.36 | 56.24 | |
| Depreciation And Amortisation Expenses | 95.46 | 82.41 | 74.60 | 71.84 | 51.12 | |
| Other Expenses | 213.28 | 223.67 | 175.14 | 126.37 | 91.53 | |
| Total Expenses | 2,652.82 | 2,441.64 | 2,050.71 | 1,745.36 | 1,326.71 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 709.27 | 156.08 | 339.24 | 225.88 | 88.95 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 709.27 | 156.08 | 339.24 | 225.88 | 88.95 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 167.42 | 29.00 | 48.35 | 3.50 | 0.92 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 16.67 | 5.94 | 5.24 | -4.06 | 15.88 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 184.09 | 35.45 | 54.06 | -0.16 | 17.08 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 525.18 | 120.63 | 285.18 | 226.04 | 71.87 | |
| Profit/Loss From Continuing Operations | 525.76 | 128.54 | 290.78 | 229.08 | 69.38 | |
| Profit/Loss For The Period | 525.76 | 128.54 | 290.78 | 229.08 | 69.38 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 94.36 | 23.91 | 54.09 | 42.95 | 13.03 | |
| Diluted EPS (Rs.) | 94.36 | 23.91 | 54.09 | 42.95 | 13.03 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 1,289.92 | 1,178.38 | 951.95 | 901.68 | 666.39 | |
| Indigenous Raw Materials | 587.83 | 362.55 | 352.32 | 246.66 | 221.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 3.03 | 1.83 | 0.95 | 0.49 | 0.35 | |
| Indigenous Stores And Spares | 35.84 | 30.66 | 30.60 | 27.14 | 16.06 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 27.74 | 24.20 | 17.57 | 13.34 | 8.12 | |
| Tax On Dividend | 4.67 | 4.11 | 2.98 | 2.27 | 1.16 | |
| Equity Dividend Rate (%) | 100.00 | 90.00 | 65.00 | 50.00 | 30.00 |
07.01.2026
02.01.2026
19.12.2025
15.12.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL